Avantor (NYSE: AVTR - Get Free Report) and LifeMD (NASDAQ: LFMD - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 95.1% of Avantor shares are owned
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of LifeMD, Inc. (NASDAQ: LFMD) breached their fiduciary duties to shareholders.
Shares of LifeMD, Inc. (NASDAQ: LFMD - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to
New York, New York--(Newsfile Corp. - January 22, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of LifeMD, Inc. (NASDAQ: LFMD) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at LifeMD caused the company to misrepresent or fail to disclose that: (1) LifeMD's competitive position was materially overstated; (2) raising LifeMD's 2025 guidance was reckless because rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound had not properly been accounted for; and (3) as a result, statements about LifeMD's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Concentra Group Holdings Parent (NYSE: CON - Get Free Report) and LifeMD (NASDAQ: LFMD - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership. Analyst Ratings This is a breakdown of
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was drawn on the RCF as the Company believes its cash on hand and expected cash flow are sufficient to fund its organic growth initiatives.
Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options
Eurofins Scient (OTCMKTS:ERFSF - Get Free Report) and LifeMD (NASDAQ: LFMD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of recent ratings
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026.
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME's America's Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD's continued revenue growth, financial stability, and emerging leadership position in the health technology sector.
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories.
TDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.
LifeMD, Inc. ( LFMD ) Q3 2025 Earnings Call November 17, 2025 4:30 PM EST Company Participants Justin Schreiber - Chairman & CEO Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Sarah James - Cantor Fitzgerald & Co., Research Division Eduardo Martinez-Montes - H.C.
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.14 per share a year ago.
LifeMD Inc. (NASDAQ: LFMD) shares fell after the company released its third-quarter earnings report after Monday's closing bell, missing analyst estimates on the top and bottom lines.
Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million.
LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care
Campbell and CO Investment Adviser LLC bought a new position in shares of LifeMD, Inc. (NASDAQ: LFMD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 26,361 shares of the company's stock, valued at approximately $359,000. Campbell and CO Investment Adviser LLC
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Acadian Asset Management LLC bought a new position in LifeMD, Inc. (NASDAQ: LFMD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 281,244 shares of the company's stock, valued at approximately $3,828,000. Acadian Asset Management LLC owned about 0.62% of LifeMD at the